We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Boundless Bio Inc (BOLD) USD0.0001

Sell:$2.73 Buy:$2.77 Change: $0.1 (3.45%)
NASDAQ:0.16%
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Sell:$2.73
Buy:$2.77
Change: $0.1 (3.45%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Sell:$2.73
Buy:$2.77
Change: $0.1 (3.45%)
Market closed |  Prices as at close on 2 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.

Contact details

Address:
9880 Campus Point Drive, Suite 120
SAN DIEGO
92121
United States
Telephone:
+1 (858) 7669912
Website:
https://boundlessbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BOLD
ISIN:
US10170A1007
Market cap:
$64.67 million
Shares in issue:
22.30 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Zachary Hornby
    President, Chief Executive Officer, Director
  • David Hinkle
    Principal Financial Officer, Principal Accounting Officer, Treasurer
  • Christian Hassig
    Chief Scientific Officer
  • Neil Abdollahian
    Chief Business Officer
  • Klaus Wagner
    Chief Medical Officer
  • Jessica Oien
    Chief Legal Officer and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.